Search This Blog

Tuesday, June 9, 2015

Lilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes (NYSE:LLY)

Data from Phase III Clinical Trial Program Presented at the 2015 American Diabetes Association Scientific Sessions®



Lilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.